Enthera Pharmaceuticals appoints Aled Williams as Chief Executive Officer

Milan, Italy, 4 May, 2022 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, today announces the appointment of Aled Williams as Chief Executive Officer and member of its Board of Directors.

Aled has over twenty-five years of experience as a senior executive in the biotechnology and pharmaceutical sectors, with a strong track record of success across multiple therapeutic areas. He has been responsible for corporate and portfolio strategy, devising R&D and market access strategies, as well as leading commercial product launches.

Aled joins Enthera from Polyneuron Pharmaceuticals AG, where he served as Chief Business Officer. Prior to this, he was Chief Commercial Officer at VectivBio and Therachon, where, as a member of the Executive team, he played a key role in the acquisition of GLyPharma Therapeutic and the subsequent acquisition of Therachon by Pfizer. Previously, he provided global, cross-functional leadership for three of Shire Pharmaceuticals’ rare disease therapeutic areas, and also worked in global leadership roles at Bristol-Myers Squibb, Novartis and Roche.

Silvano Spinelli, Chairman of the Board at Enthera, said: “We are delighted to welcome Aled as Enthera’s CEO. His background and breadth of C-suite level experience will be essential for moving Enthera’s pipeline forward into the clinic. His considerable background with big pharma will also be key for our clinical and business development strategies.”

Aled Williams, commented: “I am delighted to be joining Enthera at such a pivotal time, ahead of the Company’s lead candidate moving into the clinic. Enthera’s regenerative immunology concept is an innovative approach for underserved autoimmune disorders and pre-clinical results show great potential. I’m looking forward to leading the team in these exciting times.”

Aled holds a bachelor’s degree in Microbiology and a Postgraduate Diploma in Management Studies.

For more information please contact:

Enthera Pharmaceuticals

Silvano Spinelli, Chairman
Aled Williams, CEO
E: info@entherapharmaceuticals.com

Instinctif Partners (media enquiries)
Melanie Toyne-Sewell / Agnes Stephens / Siobhan Sanford
Tel: +44 20 7457 2020
E: enthera@instinctif.com

About Enthera

Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Company’s primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

Enthera’s pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.

The Company is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-establish organ function.

Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof Paolo Fiorina and Dr Francesca D’Addio at BiovelocITA, an Italian biotech accelerator. The Company is backed by Sofinnova Partners, AbbVie INC, JDRF T1D Fund, Roche Finance LTD and a number of private investors. Enthera’s discovery engine and assets are protected by a broad portfolio of patents.

For more information, visit https://www.entherapharmaceuticals.com/

Connect with us on LinkedIn.